Clinical trial
Cognitive Protective Effect of Newer Antidiabetic Drugs
NCT05347459
Study timeline
Study start (actual)2022-03-02Date precision: day
Registry last updated2022-07-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetesunresolved
Interventions
DapagliflozinDRUG · verified · RxNorm: dapagliflozin
EmpagliflozinDRUG · verified · RxNorm: empagliflozin
CanagliflozinDRUG · verified · RxNorm: canagliflozin
SitagliptinDRUG · verified · RxNorm: sitagliptin
SaxagliptinDRUG · verified · RxNorm: saxagliptin
LinagliptinDRUG · verified · RxNorm: linagliptin
VildagliptinDRUG
Sponsors & collaborators
Alexandria Universitylead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05347459 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.